文献速递心脑血管急症重症综合管理与镇静镇痛

全身炎症早期标志物与动脉瘤性蛛网膜下腔出血后疼痛负担无关:一项多中心观察性研究

Early Markers of Systemic Inflammation are not Related to Pain Burden After Aneurysmal Subarachnoid Hemorrhage: A Multicenter Observational Study.
PubMed 文献 · Neurocrit Care · 2025-10-22
一句话结论在动脉瘤性蛛网膜下腔出血患者中,年轻年龄和慢性阿片类药物使用与ICU疼痛负担较高相关,而血液炎症生物标志物与疼痛负担无关。

本研究为回顾性多中心观察性研究,纳入523例动脉瘤性蛛网膜下腔出血患者,按每日平均疼痛负担四分位分组,采用单因素分析和有序logistic回归识别疼痛负担预测因素。结果显示,年龄较大与较低的ICU疼痛负担相关(OR 1.01,95%CI 1.01-1.03),慢性阿片类药物使用与较高的ICU疼痛负担相关(OR 0.59,95%CI 0.38-0.90),而血液炎症生物标志物在单因素和多因素分析中均与高ICU疼痛负担无关。在能够口头报告疼痛评分的亚组中结果相似。结论认为,年轻年龄和慢性阿片类药物使用与较高ICU疼痛负担相关,炎症血液生物标志物缺乏关联,需进一步研究阐明持续疼痛的生物学通路和心理社会决定因素。

要点

  • 在523例动脉瘤性蛛网膜下腔出血患者中,年龄较大与较低的ICU疼痛负担相关(OR 1.01,95%CI 1.01-1.03)。
  • 慢性阿片类药物使用与较高的ICU疼痛负担相关(OR 0.59,95%CI 0.38-0.90)。
  • 血液炎症生物标志物在单因素和多因素分析中均与高ICU疼痛负担无关。
  • 在能够口头报告疼痛评分的患者亚组中,上述结果相似。
  • 作者认为,需进一步研究阐明动脉瘤性蛛网膜下腔出血后持续疼痛的生物学通路和心理社会决定因素。

适用人群与场景

  • 动脉瘤性蛛网膜下腔出血患者,最终分析523例,平均年龄55岁,352例(67%)为女性,中位Hunt-Hess评分3分(四分位距2-3),465例(89%)改良Fisher评分3或4分。
  • 研究场景为ICU病程中的疼痛负担评估。
  • 敏感性分析限定于ICU期间能够口头报告疼痛评分的患者。

研究设计与关键结果

  • 研究类型为回顾性、多中心观察性研究,最终分析523例动脉瘤性蛛网膜下腔出血患者。
  • 疼痛评分从电子健康记录中提取,研究参与者根据每日平均疼痛负担分为四分位组。
  • 预测因素通过单因素分析和有序logistic回归识别。
  • 年龄较大与较低的ICU疼痛负担相关(OR 1.01,95%CI 1.01-1.03)。
  • 慢性阿片类药物使用与较高的ICU疼痛负担相关(OR 0.59,95%CI 0.38-0.90)。
  • 血液炎症生物标志物在单因素和多因素分析中均与高ICU疼痛负担无关。
  • 在能够口头报告疼痛评分的患者亚组中结果相似。

证据类型、等级与局限

  • 证据类型:回顾性、多中心观察性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,需进一步研究阐明动脉瘤性蛛网膜下腔出血后持续疼痛的生物学通路和心理社会决定因素。
  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Headache is nearly ubiquitous in the immediate aftermath of nontraumatic, aneurysmal pattern subarachnoid hemorrhage (SAH); however, pain experiences vary significantly throughout the intensive care unit (ICU) course across patients and may challenge the establishment of effective analgesic treatment. Acute abortive management often relies on opioids. The pathophysiologic factors driving persistent pain after SAH are likely related to the inflammatory response to blood-brain barrier breakdown and heme degradation. Scarce data on predictors for a course of refractory headache preclude the ability to risk stratify and identify patients who could benefit from targeted, opioid-sparing pain management strategies. We aimed to identify clinical and laboratory predictors of a persistently high pain burden during the ICU course.

METHODS: We performed a retrospective, multicenter observational study in patients with SAH. Pain scores were abstracted from the electronic health record. Study participants were divided into quartiles based on the average burden of daily pain, and predictors of pain burden were identified by univariate analysis and ordinal logistic regression. We performed a sensitivity analysis restricted to patients able to verbally report pain scores in the ICU.

RESULTS: Of the 523 patients in the final analysis, the mean age was 55 years, 352 (67%) were female, the median Hunt-Hess score was 3 (interquartile range 2-3), and 465 (89%) had a modified Fisher score of 3 or 4. Older age was associated with lower ICU pain burden (odds ratio 1.01, 95% confidence interval 1.01-1.03). Chronic opioid use (odds ratio 0.59, 95% confidence interval 0.38-0.90) was associated with a higher ICU pain burden. Conversely, blood inflammatory biomarkers were not associated with high ICU pain burden in the univariate or multivariate analysis. The results were similar among the subgroup of patients able to verbally report pain scores throughout admission.

CONCLUSIONS: In this multicenter study, young age and chronic opioid use are associated with higher ICU pain burden, whereas inflammatory blood biomarkers lack an association. Further study is required to elucidate the biological pathways and psychosocial determinants of protracted pain after aneurysmal SAH.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Kardon A, Ren H, Gerard E, et al. Early Markers of Systemic Inflammation are not Related to Pain Burden After Aneurysmal Subarachnoid Hemorrhage: A Multicenter Observational Study. Neurocrit Care. 2025. PMID: 41125902. doi:10.1007/s12028-025-02396-w

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。